A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep

Clinical and Experimental Allergy

Volumn 39, Issue 9, 2009, Pages 1404-1414

  Shichijo, M ^a   Arimura, A ^b   Hirano, Y ^a   Yasui, K ^a   Suzuki, N ^a   Deguchi, M ^a   Abraham, W M ^c  

^a SHIONOGI AND CO LTD   (Japan)

^b Strategic Development Department   (Japan)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Asthma; PGD2; Prostanoid DP1 receptor; S 5751; Sheep

Indexed keywords

7 [2 (5 HYDROXYBENZO[B]THIOPHEN 3 YLCARBONYLAMINO) 10 NORPINAN 3 YL]HEPT 5 ENOIC ACID; ALLERGEN; ANTIGEN; CYCLIC AMP; LEUKOTRIENE D4; MONTELUKAST; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTANOID DP1 RECEPTOR; PROSTANOID RECEPTOR; S 5751; UNCLASSIFIED DRUG; 7(2 (5 HYDROXYBENZO(B)THIOPHEN 3 YLCARBONYLAMINO) 10 NORPINAN 3 YL)HEPT 5 ENOIC ACID; 7(2-(5-HYDROXYBENZO(B)THIOPHEN-3-YLCARBONYLAMINO)-10-NORPINAN-3-YL)HEPT-5-ENOIC ACID; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN RECEPTOR; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; QUINOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCARIS SUUM; ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LUNG LAVAGE; LUNG RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHEEP; THROMBOCYTE RICH PLASMA; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; TIME;

ACETATES; ALLERGENS; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOCONSTRICTION; CYCLIC AMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; PROSTAGLANDIN D2; QUINOLINES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; THIOPHENES; TIME FACTORS;

EID: 68349137905     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03275.x     Document Type: Article

References (33)

1. 2 generation after the activation of rat and human mast cells with anti-IgE. J Immunol 1982 129 : 1627 31.
2. 2 into human airways during acute antigen challenge. N Engl J Med 1986 315 : 800 4.
3. 2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur Respir J 1995 8 : 411 5.
4. Woodward DF, Nieves AL, Friedlaender MH. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritis and their role in mediating allergic conjunctival itching. J Pharmacol Exp Ther 1996 279 : 137 42.
5. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001 193 : 255 61.
6. Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol 2008 153 (Suppl. 1) : S191 9.
7. 2 as a mediator of allergic asthma. Science 2000 287 : 2013 7.
8. Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 2003 171 : 3936 40.
9. Hammad H, Kool M, Soullié T et al. Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med 2007 204 : 357 67.
10. Spik I, Brénuchon C, Angéli V et al. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 2005 174 : 3703 8.
11. Arimura A, Yasui K, Kishino J et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 2001 298 : 411 9.
12. Mitsumori S, Tsuri T, Honma T et al. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2.6,6-dimethylbicyclo[3.1.1]heptane derivatives. J Med Chem 2003 46 : 2446 55.
13. Abraham WM. Animal models of asthma. In : Busse WW, Holgate ST, eds. Asthma & Rhinitis. Oxford : Blackwell Science, 2000 1205 1227.
14. Abraham WM, Burch RM, Farmer SG, Sielczak MW, Ahmed A, Cortes A. A bradykinin antagonist modifies allergen-induced mediator release and late bronchial responses in sheep. Am Rev Respir Dis 1991 143 : 787 96.
15. 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 1994 93 : 776 87.
16. Abraham WM, Gill A, Ahmed A et al. A small-molecule, tight binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med 2000 162 : 603 11.
17. Abraham WM, Ahmed A, Serebriakov I et al. A monoclonal antibody to a1b1 blocks antigen-induced airway responses in sheep. Am J Respir Crit Care Med 2004 169 : 97 104.
18. Abraham WM, Ahmed A, Sabater JR et al. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med 1999 159 : 1205 14.
19. Rosen SD, Tsay D, Singer MS, Hemmerich S, Abraham WM. Therapeutic targeting of endothelial ligands for l-selectin (PNAd) in a sheep model of asthma. Am J Pathol 2005 166 : 935 44.
20. Jones TR, Labelle M, Belley M et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995 73 : 191 201.
21. Abraham WM. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 2008 21 : 743 54.
22. Sugimoto H, Shichijo M, Iino T et al. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003 305 : 347 52.
23. Sabater JR, Wanner A, Abraham WM. Montelukast prevents antigen-induced mucociliary dysfunction in sheep. Am J Respir Crit Care Med 2002 166 : 1457 60.
24. Drummond WH, Carter RL. Cardiac depressant and circulatory effects of prostaglandin D2 in developing lambs. Am J Physiol 1987 252 (Part 2) : H374 83.
25. Jones TR, Prostanoid DP. Receptor for respiratory disease. 12th Biennial Conference of the inflammation Research Association, New York: Bolton Landing, 2004.
26. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000 356 : 2144 8.
27. O'Byrne PM. The Demise of Anti-IL-5 for Asthma, or Not. Am J Respir Crit Care Med 2007 176 : 1059 60.
28. Flood-Page P, Swenson C, Faiferman I et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Respir Crit Care Med 2007 176 : 1062 71.
29. Pradalier A. Late-phase reaction in asthma: basic mechanisms. Int Arch Allergy Immunol 1993 101 : 322 5.
30. Boxer LA, Axtell R, Suchard S. The role of the neutrophil in inflammatory diseases of the lung. Blood Cells 1990 16 : 25 42.
31. Shichijo M, Deguchi M, Hirano Y, Asanuma F, Arimura A. Effect of a novel prostaglandin D2 antagonist, S-5751, on antigen-induced pulmonary responses in guinea pigs. Am J Res Crit Care Med 2007 175 : A494.
32. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999 14 : 12 8.
33. Shahbazian A, Heinemann A, Peskar BA, Holzer P. Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestine. Br J Pharmacol 2002 137 : 1047 54.